GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure Of Related Party Transactions Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the disclosure of Related Party Transactions on a consolidated basis drawn in accordance with the relevant accounting standards for the period ended 31st March, 2020. Covid treatment: Brinton Pharma's Favipiravir tab set to trigger a price-war
Prices Faviton at 59/tab against 75 for Glenmark's FabiFlu
Glenmark says trial showed favipiravir use led to 40% faster cure from covid-19
Recovery from symptoms like fever, respiratory rate, oxygen saturation and cough relief were the secondary endpoint of 150-patient trial, while the primary endpoint was the time taken to stop oral shedding of the virus, which indicates contagiousness of the infected person GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Announces Top-Line Results from Phase 3 Clinical Trial of Favipiravir in Patients with Mild to Moderate COVID-19 Phase 3 Trial Demonstrates Statistically Significant Faster Time to Clinical Improvement with Favipiravir Treatment in Mild to Moderate COVID 19 Patients Compared to Control Top headlines: Glenmark defends FabiFlu, Covid antibody in Delhi residents
Here are the top headlines of the day Glenmark defends pricing of Covid-19 drug FabiFlu, says it is economical
Glenmark also denies making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate Covid-19 patients GLENMARK PHARMACEUTICALS LTD. - 532296 - Clarification
Clarification on news item appeared in Media/Publication GLENMARK PHARMACEUTICALS LTD. - 532296 - Shareholding for the Period Ended June 30, 2020
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here GLENMARK PHARMACEUTICALS LTD. - 532296 - Clarification sought from Glenmark Pharmaceuticals Ltd
The Exchange has sought clarification from Glenmark Pharmaceuticals Ltd with respect to news article appearing on www.business-standard.com July 20, 2020 titled "Glenmark under fire for over pricing, 'misguided' claims of Covid-19 drug".The reply is awaited. GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark launches world''s first Hypertension Awareness symbol, endorsed by Association of Physicians of India (API) & Hypertension Society of India (HSI) Also pledges on-ground screening of 5 million people for high BP in India